Twist Bioscience Co. (NASDAQ:TWST) CEO Sells $587,872.05 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 13,605 shares of Twist Bioscience stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total value of $587,872.05. Following the completion of the sale, the chief executive officer now directly owns 481,918 shares of the company’s stock, valued at $20,823,676.78. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Twist Bioscience Stock Up 1.3 %

Shares of Twist Bioscience stock opened at $43.34 on Monday. The stock’s 50-day simple moving average is $44.94 and its 200-day simple moving average is $43.75. Twist Bioscience Co. has a 52 week low of $14.42 and a 52 week high of $60.90. The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of -12.90 and a beta of 1.77.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business had revenue of $81.50 million during the quarter, compared to analysts’ expectations of $77.40 million. During the same quarter in the previous year, the firm earned ($1.01) earnings per share. Twist Bioscience’s revenue was up 27.7% on a year-over-year basis. On average, equities analysts expect that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on TWST shares. Evercore ISI lifted their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. The Goldman Sachs Group lifted their price objective on Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, July 9th. Robert W. Baird lifted their price objective on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. JPMorgan Chase & Co. boosted their price target on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Finally, TD Cowen boosted their price target on Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, June 13th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus price target of $51.63.

Hedge Funds Weigh In On Twist Bioscience

Large investors have recently made changes to their positions in the business. EdgeRock Capital LLC purchased a new stake in shares of Twist Bioscience in the second quarter worth about $43,000. Blue Trust Inc. lifted its position in shares of Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after buying an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Twist Bioscience in the second quarter worth about $61,000. Nisa Investment Advisors LLC lifted its position in shares of Twist Bioscience by 31.3% in the second quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock worth $113,000 after buying an additional 546 shares in the last quarter. Finally, CWM LLC lifted its position in shares of Twist Bioscience by 27.4% in the second quarter. CWM LLC now owns 2,437 shares of the company’s stock worth $120,000 after buying an additional 524 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.